Scarica l'app Stockscreener
12.52
3.63%
-0.4796
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RLAY Giù?
Forum
Previsione
Relay Therapeutics Inc Borsa (RLAY) Ultime notizie
Relay Therapeutics Q1 Loss Narrows, Revenue Fall - marketscreener.com
Relay Therapeutics, Inc. (RLAY) reports Q1 loss, lags revenue estimates - MSN
Relay Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates - Investing News Network
Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Relay Therapeutics (NASDAQ:RLAY) Beats Q1 Estimates but Slips on Wider Loss and Lack of Guidance - ChartMill
Earnings Flash (RLAY) Relay Therapeutics, Inc. Reports Q1 Revenue $3.0M, vs. FactSet Est of $5.6M - marketscreener.com
Relay breast cancer drug gets FDA breakthrough, Phase 3 next - Stock Titan
Earnings Flash (RLAY) Relay Therapeutics, Inc. Reports Q1 Revenue $3.0M, Vs. FactSet Est of $5.6M - Moomoo
[10-Q] Relay Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Relay Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
FDA BTD, trial advances and 2029 cash runway for Relay Therapeutics (Nasdaq: RLAY) - Stock Titan
Relay Therapeutics Q1 2026 earnings preview - MSN
MSN Money - MSN
Relay Therapeutics Inc (RLAY) Stock News & Articles - 24/7 Wall St.
Relay Therapeutics Advances Zovegalisib To Phase 3 As Valuation Gap Persists - Yahoo Finance
Relay Therapeutics Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Insider Selling: Relay Therapeutics (NASDAQ:RLAY) Insider Sells 1,490 Shares of Stock - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Insider Sells $11,136.87 in Stock - MarketBeat
Relay Therapeutics: Peter Rahmer sells $11,136 in common stock - Investing.com UK
Relay Therapeutics: Peter Rahmer sells $11,136 in common stock By Investing.com - Investing.com India
Relay Therapeutics CFO Catinazzo sells $14,375 in stock - Investing.com
Relay Therapeutics CFO Catinazzo sells $14,375 in stock By Investing.com - Investing.com Australia
[Form 4] Relay Therapeutics, Inc. Insider Trading Activity - Stock Titan
Relay Therapeutics (RLAY) executive sells 753 shares to cover RSU taxes - Stock Titan
Relay Therapeutics (NASDAQ: RLAY) exec sells 1,490 shares for taxes - Stock Titan
H.C. Wainwright Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $25 - Moomoo
Earnings Preview: RLAY to Report Financial Results Post-market on May 05 - Moomoo
Relay Therapeutics Shares Fall After Significant Monthly Price Surge - HarianBasis.co
Analysts Are Betting On Relay Therapeutics, Inc. (NASDAQ:RLAY) With A Big Upgrade This Week - simplywall.st
Relay Therapeutics, Inc. (NASDAQ:RLAY) Short Interest Update - MarketBeat
Relay Therapeutics Call Puts Zovegalisib Breast Cancer Prospects In Focus - Sahm
Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on ... - Caledonian Record
Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026 - marketscreener.com
Relay Therapeutics (RLAY) surges 16.4%: Is this an indication of further gains? - MSN
Relay Therapeutics Is Maintained at Buy by HC Wainwright & Co. - Moomoo
RLAY Maintained by HC Wainwright & Co. -- Price Target Raised to $25 - GuruFocus
A Quick Look at Today's Ratings for Relay Therapeutics(RLAY.US), With a Forecast Between $18 to $25 - Moomoo
H.C. Wainwright raises Relay Therapeutics stock price target to $25 By Investing.com - Investing.com Canada
RLAY Maintained by Wells Fargo -- Price Target Raised to $21.00 - GuruFocus
Relay Therapeutics (RLAY) Falls Hard on Profit-Taking From 74% April Jump - Insider Monkey
[ARS] Relay Therapeutics, Inc. SEC Filing - Stock Titan
Relay Therapeutics (NASDAQ: RLAY) 2026 proxy details director, pay and share votes - Stock Titan
A Quick Look at Today's Ratings for Relay Therapeutics(RLAY.US), With a Forecast Between $18 to $22 - Moomoo
Relay Therapeutics (NASDAQ:RLAY) Shares Down 7.9%Here's Why - MarketBeat
RLAY Stock Slides As Traders Eye Support And Cash Runway - StocksToTrade
RLAY Maintained by Goldman Sachs -- Price Target Raised to $22.00 - GuruFocus
RLAY Maintained by Citizens -- Price Target Raised to $19.00 - GuruFocus
RLAY Maintained by Oppenheimer -- Price Target Raised to $18.00 - GuruFocus
Citizens Jmp Raises Relay Therapeutics (NASDAQ:RLAY) Price Target to $19.00 - MarketBeat
0.78%
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):